Accurate detection of the microorganisms underlying gut dysbiosis in the patient is critical to 15 initiate the appropriate treatment. However, most clinical microbiology techniques used to detect 16 gut bacteria were developed over a century ago and rely on culture-based approaches that are 17 often laborious, unreliable, and subjective. Further, culturing does not scale well for multiple 18 targets and detects only a minority of the microorganisms in the human gastrointestinal tract. 19
Introduction 33
Although most microorganisms living within the human host are thought to be harmless or even 34 beneficial [1], some of the deadliest diseases and epidemics in human history have been 35 caused by bacteria [2] . Microbial infections remain a major cause of death and disease 36 worldwide to this day [3] . In addition, the gut microbiome is now recognized as playing a major 37 role in health maintenance and there are clear associations between a microbiome imbalance 38 (dysbiosis) and various diseases and medical conditions [4] . Bacteria in the gastrointestinal tract 39 have been long known to underlie numerous illnesses such as diarrhea and food poisoning. 40
More recently, specific bacteria and associated inflammation have been shown to promote 41 broader gastrointestinal diseases including irritable bowel syndrome [5] and cancer [6] . 42
Rapid and accurate identification of causative microorganisms is critical to provide the 43 appropriate treatment for patients suffering from these gastrointestinal conditions. However, 44 clinical microbiology still largely depends on traditional culturing methods to identify etiological 45 agents. Culture techniques have remained essentially the same for the last 50 years [7] . The 46 specialized work of culturing specific microorganisms is laborious, time-consuming and requires 47 interpretation by extensively trained personnel. Moreover, many organisms are not cultivable 48 and causative agents often fail to grow on culture even when present [8, 9] . Alternative 49 techniques to accurately report the composition of the gut microbiome in a timely manner are 50 clearly necessary to improve clinical practice and patient outcome [10] . 51
Next-generation sequencing (NGS) technology [11] can be used to detect prokaryotic 52 16S rRNA gene sequences within clinical samples, and has the potential to replace culture-53 based strategies for determining the composition of microbiomes [12, 13] . The implementation 54 and consolidation of clinical microbiological tests with NGS would enable rapid, accurate, and 55 reliable detection of all bacteria and archaea present within a sample, including their relative 56 levels, using the 16S rRNA gene sequence as a molecular marker and identifier [4, 14, 15] . 57 Furthermore, multiplexing allows multiple samples to be processed at the same time, reducing 58 labor and cost, while taxonomic classification can be automated, reducing the need for manual 59 clinical interpretation. Indeed, the identification of prokaryotes by 16S rRNA gene sequencing is 60 in widespread use with many successful examples, including rapid pathogen sequencing [15] , 61 microbiome analyses [16] [17] [18] , and the detection of polymicrobial infections [19] . Compared to 62 traditional clinical microbiology, 16S rRNA sequencing is not only a superior process, but also 63 has a greatly improved sampling procedure (Fig 1) . Sequencing requires significantly less 64 material, which eases the patient burden of sample collection, particularly from sources such as 65 fecal matter. Further, the microbial population within the sample is immediately processed by 66 microbial lysing and DNA stabilization, precluding artifacts that might arise after collection. 67
Although ease of sampling is obviously subjacent to accurate detection, it likely facilitates 68 regular sampling for personal health monitoring and public health surveillance. 69
In contrast to culturing, 16S rRNA gene sequencing can simultaneously detect and 70 quantify numerous bacteria and archaea in a sample. This eliminates the need for physicians to 71 select specific clinical targets for culturing and also creates an opportunity to observe the overall 72 state of the microbiome. This is of particular clinical interest since, concurrent with the advent of 73 NGS, the microbiome has emerged as a major contributor to human health and disease [4] . The 74 gut microbiome especially plays an important role in achieving optimal human health, with 75 demonstrated impacts on aging, metabolic syndrome and immunity. Although medical diagnosis 76 has traditionally focused on pathogens, these overarching and interrelated conditions appear to 77 be greatly influenced by the composition of the commensal gut microbiome. Regularly 78 evaluating the microbiome to monitor overall health is therefore gaining traction in contemporary 79 medicine and needs to be part of modern diagnostics. 80
In this study, we present the development and validation of a novel NGS-based clinical 81 gut microbiome detection assay. The assay utilizes 16S rRNA gene sequencing to identify 28 82 clinically relevant microbial targets, 14 species and 14 genera, that comprise pathogens and 83 commensals from the human gastrointestinal tract. 84 
Taxonomic Annotation and Reference Database Generation

110
After sequencing, demultiplexing of samples was performed using Illumina's BCL2FASTQ 111 algorithm. Reads were filtered using an average Q-score > 30. Forward and reverse reads were 112 appended together and clustered using the Swarm algorithm [21] using a distance of 1 113 nucleotide. The most abundant sequence per cluster was considered the real biological 114 sequence and was assigned the count of all reads in the cluster. The remainder of the reads in 115 a cluster were considered to contain errors as a product of sequencing. The representative 116 reads from all clusters were subjected to chimera removal using the VSEARCH algorithm [22] . 117
Clustered reads passing all above filters were aligned using 100% identity over 100% of the 118 length against a hand-curated database of target 16S rRNA gene sequences derived from 119 version 123 of the SILVA database [23]. The hand-curated databases for each taxa were 120 created by selectively removing sequences with amplicons that were ambiguously annotated to 121 more than one taxonomic group, while still maximizing the sensitivity, specificity, precision and 122 negative predictive value of identification for the remaining amplicons in each taxa (S1 Doc). 123
The relative abundance of each taxa was determined by dividing the count linked to that taxa by 124 the total number of reads passing all filters. 125
Participants 126
Samples from 1,000 self-reported healthy individuals were selected from the ongoing uBiome 127 citizen science microbiome research study (manuscript in preparation). 103 samples did not 128 pass our 10,000 read quality control threshold, resulting in a healthy cohort of 897 samples 129 (62% male and 38% female). Participants were explicitly asked about 42 different medical 130 conditions such as cancer, infections, obesity, chronic health issues and mental health 131 disorders. Selected participants with an average age of 39.7 years (SD = 15.5) responded to an 132 extensive survey and self-reported to be currently and overall in good health. None of the 133 individuals selected for the healthy cohort had ever been diagnosed with high blood sugar, 134 diabetes, gut-related symptoms or any other medical condition. This study was performed under 135 a Human Subjects Protocol provided by an IRB. Informed consent was obtained from all 136 participants. Analysis of participant data was performed in aggregate and anonymously. 137
Experimental verification
138 Double-stranded DNA segments were designed to be representative for the V4 region of the 139 16S rRNA gene of each target species or genus and synthesized by IDT and Thermo Fisher. 140
Two sets of 14 targets each were combined at 1:10, 1:50, 1:100 and 1:1000 ratios and vice 141 versa, allowing for the detection of different levels of targets in a high background of DNA (the 142 undiluted set). The resulting ratios are 1:14014, 1:1414, 1:714, 1:154 and ~1:14 (1000:14014 for 143 the undiluted set) for each individual target (S1 Fig) . The amount of DNA for each target was 144 1.74 pg (6.078 attomoles) before dilution. Sample combinations were processed in uBiome 145 microbiome sampling kits using the clinical pipeline described above. related conditions. Ultimately, we compiled a preliminary target list containing 15 genera and 31 168 species of microorganisms associated with human health status (S1 Table) , including 169 pathogenic, commensal and probiotic bacteria and archaea. 170
The bioinformatics annotation pipeline developed for this clinical test was specifically 171 designed to have high prediction performance. To this end, we implemented a taxonomy 172 annotation based on sequence searches of 100% identity over the entire length of the 16S 173 rRNA gene V4 region from the preliminary targets in our database (S1 Doc). Curated databases 174
were generated for each of the taxa in our preliminary target list using the performance metrics 175 sensitivity, specificity, precision and negative predictive value as optimizing parameters. In other 176 words, the bioinformatics pipeline was optimized to ensure that a positive result on the test truly 177 means the target is present in the sample and a negative result is only obtained when no target 178 is present in the sample. After optimizing the confusion matrices for all preliminary targets, 28 179 out of 46 targets passed our stringent threshold of 90% for each of the parameters (Fig 2) . The 180 resulting target list is composed of 5 known pathogens, 3 beneficial bacteria, and 20 additional 181 microorganisms related to various gut afflictions, as well as commensal bacteria and one 182 archeon. On average the sensitivity, specificity, precision and negative prediction value of the 183 bacteria on our target list are 99.0%, 100%, 98.9% and 100%, for the species, and 97.4%, 184 100%, 98.5% and 100% for the genera, respectively. 185 within the microbial population. This analysis gave rise to a distribution of relative abundance for 207 each target in the cohort (Fig 3) . From these data, we defined a central 99% healthy range or 208 confidence interval for each target. If the relative abundance of a target is outside of this healthy 209 range within a sample, it would be considered a positive result. 210
Many of the targets show significant spread, emphasizing the importance of microbiome 211 identification in the context of a reference range. For example, the pathogen Peptoclostridium 212 difficile is found in ~2% of the healthy cohort which shows that asymptomatic P. 213 difficile colonization is not uncommon in healthy individuals [24] . Although all taxa are not found 214 to be present in at least some of the healthy individuals, the maximum of the reference range 215 can be quite high for some taxa (~63% for Prevotella and 49% for Bifidobacterium, for 216 example). Two species are not represented at all within the central 99% of the healthy cohort: 217
Vibrio cholerae and Ruminococcus albus. The absence of V. cholerae is suggestive of its 218 pathogenic nature and its relatively rare occurrence in the developed world. However, R. albus, 219 has previously been found to be enriched in healthy subjects in comparison to patients with 220
Crohn's disease [25] . healthy distribution is used to define the 99% confidence interval (red whiskers). The box 229 indicates the 25th-75th percentile, and the median coverage is indicated by a horizontal line in 230 the box. Even in this healthy cohort, many of the bacteria that are associated with poor health 231 conditions are present at some level. As most taxa are absent in a significant number of 232 individuals most boxes expand to 0%, the healthy lower limit (not shown). 233 234 Accurate detection of all 28 targets 235 To demonstrate our ability to accurately detect all the microorganisms in the clinical target list, 236
we created representative synthetic double-stranded DNA (sDNA) gene blocks for each of the 237 28 targets (S2 Table) . We analyzed the 28 targets as two sets of 14 distinct sDNA sequences. 238
These sDNA sets were combined in specific proportions, resulting in five samples of increasing 239 ratios for each target, 1:14,014, 1:1,414, 1:714 1:154 and ~1:14. We processed each sample 240 using our clinical bioinformatics pipeline. Importantly, we accurately detected all targets at each 241 ratio ( Fig 4A) , including the 1:14,014 ratio that is at our theoretical limit of detection, determined 242 by our sequencing depth of 10,000 reads per sample (results shown for five species). Our ability 243 to accurately determine the relative abundance of each target, even when it is present at 244 exceedingly low levels, suggests that we can accurately detect each target within clinical 245 samples and relate it to the healthy reference range to obtain a clinically informative result. was included in our preliminary target list, it did not pass our stringent bioinformatics QC 256 thresholds for accurate identification. As expected, the relative abundance of the 28 clinical 257 targets was in the healthy range for the Yersina positive samples, as shown for Escherichia-258 Shigella (Fig 4B) . 259 While medical diagnosis has traditionally been focused on pathogens, research on the 296 whole microbiome and its correlations with gut health continues to emerge. The test panel 297 presented here reports on some microorganisms that are not usually interrogated in the clinic 298 but provide additional insight into the overall gut health of a patient in a clinical setting. Because 299 our detection method is based on DNA sequencing, the target panel can readily be expanded if 300 new information about clinically important microorganisms arises. Because 16S rRNA gene 301 sequencing identifies and quantifies the bacteria and archaea in a sample, relevant microbial 302 metrics such as a microbiome diversity score can also be obtained, in addition to the information 303 about individual targets, to provide a comprehensive overview of gastrointestinal health [27, 28] . 304 16S rRNA gene sequencing as a clinical diagnostic tool for gut-related conditions has 305 many advantages over traditional culture-based techniques, including ease of sampling, 306 scalability of the test, no need for human interpretation, and the ability to provide additional 307 information about gut health. Thus, this method of detection for multiple clinically relevant 308 microbial targets promises to have a real impact on patient diagnoses and treatment outcomes. 309
Acknowledgements 310 This research did not receive any specific grant from funding agencies in the public, 311 commercial, or not-for-profit sectors. We thank the uBiome lab team for sample processing, the 312 bioinformatics team for data analysis, and all members of the uBiome team for helpful 313 discussions. We thank Dr. Arthur Baca, Dr. Jonathan Eisen, Dr. Joe DeRisi, Dr. Alan Greene 314 and Dr. Atul Butte for constructive input. We thank our scientific advisory board for their much-315 appreciated support. We thank Life Science Editors for editorial input. Finally, we especially 316 want to thank all citizen scientist participants of the uBiome research study for their invaluable 317 contributions. 318
